Eric Schmidt FCA
Stock Analyst at Cantor Fitzgerald
(4.87)
# 315
Out of 4,429 analysts
42
Total ratings
56.1%
Success rate
85.5%
Average return
Main Sectors:
Stocks Rated by Eric Schmidt FCA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRIM Primoris Services | Maintained: Hold | $124 | $101.30 | +22.41% | 1 | Jun 17, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | n/a | $19.07 | - | 1 | Jun 2, 2026 | |
| LONA LeonaBio | Reiterated: Buy | n/a | $8.05 | - | 2 | Apr 7, 2026 | |
| GENB Generate Biomedicines | Initiated Coverage: Buy | n/a | $14.49 | - | 1 | Mar 24, 2026 | |
| SRRK Scholar Rock Holding | Maintained: Buy | n/a | $47.33 | - | 2 | Mar 19, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 → $74 | $27.93 | +164.95% | 4 | Dec 17, 2025 | |
| VSTM Verastem | Initiated Coverage: Buy | n/a | $4.12 | - | 1 | Oct 16, 2025 | |
| ALMS Alumis | Reiterated: Buy | n/a | $23.41 | - | 3 | Aug 14, 2025 | |
| BBIO BridgeBio Pharma | Initiated Coverage: Buy | n/a | $66.27 | - | 1 | Aug 13, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiated Coverage: Buy | n/a | $7.56 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.75 | - | 8 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $35.34 | - | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.93 | n/a | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.78 | n/a | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $34.16 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $17.69 | n/a | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $311 → $206 | $196.58 | n/a | 3 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.09 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $98.22 | n/a | 1 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $27.97 | n/a | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $28.60 | n/a | 1 | Nov 2, 2023 |
Primoris Services
Jun 17, 2026
Maintained: Hold
Price Target: $124
Current: $101.30
Upside: +22.41%
Odyssey Therapeutics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.07
Upside: -
LeonaBio
Apr 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.05
Upside: -
Generate Biomedicines
Mar 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $14.49
Upside: -
Scholar Rock Holding
Mar 19, 2026
Maintained: Buy
Price Target: n/a
Current: $47.33
Upside: -
Legend Biotech
Dec 17, 2025
Maintained: Buy
Price Target: $75 → $74
Current: $27.93
Upside: +164.95%
Verastem
Oct 16, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $4.12
Upside: -
Alumis
Aug 14, 2025
Reiterated: Buy
Price Target: n/a
Current: $23.41
Upside: -
BridgeBio Pharma
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $66.27
Upside: -
BridgeBio Oncology Therapeutics
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $7.56
Upside: -
Jul 28, 2025
Reiterated: Buy
Price Target: n/a
Current: $13.75
Upside: -
Jul 25, 2025
Reiterated: Buy
Price Target: n/a
Current: $35.34
Upside: -
Jun 20, 2025
Reiterated: Hold
Price Target: n/a
Current: $8.93
Upside: n/a
Jun 2, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.78
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $34.16
Upside: n/a
Mar 21, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $17.69
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $311 → $206
Current: $196.58
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $1.09
Upside: n/a
Apr 23, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $98.22
Upside: n/a
Apr 4, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $27.97
Upside: n/a
Nov 2, 2023
Initiated Coverage: Buy
Price Target: n/a
Current: $28.60
Upside: n/a